Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.59 |
| ▸ | FAAH | O00519 | 9/20 | 0.57 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246520 | 0.86 | MGLL (0.56) | MGLLFAAHASAH1 | |
| SCHEMBL424377 | 0.84 | FAAH (0.79) | MGLLFAAH | |
| SCHEMBL13246475 | 0.79 | MGLL (0.62) | MGLLFAAHASAH1 | |
| SCHEMBL425491 | 0.78 | FAAH (0.76) | MGLLFAAHASAH1 | |
| SCHEMBL916881 | 0.78 | MGLL (0.73) | MGLLFAAHASAH1 | |
| SCHEMBL13344700 | 0.76 | MGLL (0.58) | MGLLFAAHASAH1 | |
| SCHEMBL11996927 | 0.75 | MGLL (0.56) | MGLLFAAHASAH1 | |
| SCHEMBL3231181 | 0.74 | MGLL (0.65) | MGLLFAAHASAH1 | |
| SCHEMBL917630 | 0.74 | MGLL (1.00) | MGLLFAAH | |
| SCHEMBL13246543 | 0.74 | MGLL (0.59) | MGLLFAAHASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | MGLL 5/4885FAAH 150/4885ASAH1 91/4885 |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | MGLL 5/4885FAAH 150/4885ASAH1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.